News Center

Izokibep Demonstrates Major Disease Control on ACR70, PASI100 and Enthesitis Resolution in Patients with Active Psoriatic Arthritis Treated Through 46 Weeks

Izokibep, a Unique IL-17A Inhibitor, Improves Patient-Reported Outcomes in Patients with Active Psoriatic Arthritis up to Week 46 – Phase 2 RCT Results

Izokibep Demonstrates HiSCR100 Reponses in Moderate-to-Severe Hidradenitis Suppurativa at Week 12

ACELYRIN, INC. Hosts KOL Panel Discussion at ACR Convergence 2022 on Role of Enthesitis in PsA and AxSpA

Data from Global Phase 2 Trial of Izokibep in Patients with Psoriatic Arthritis

Achievement of Different Treatment Targets with Izokibep in Psoriatic Arthritis at 16- and 46-Weeks

Izokibep - Preclinical development and first-in-human study of a novel IL-17A neutralizing Affibody molecule in patients with plaque psoriasis

Izokibep for the treatment of moderate-to-severe plaque psoriasis - a phase II, randomized, placebo-controlled, double-blind, dose-finding multicentre study including long-term treatment

NANOS 2022 Poster 293: Lonigutamab Phase 1a Single-Ascending Dose Summary, March 2023

ACR 2022 Poster 2151: PsA Phase 2 Enthesitis and Additional Outcomes, November 2022

ACR 2022 Poster 1099: PsA Phase 2 Patient Reported Outcomes, November 2022